Histidine

Histidine

SCHEMBL29670800

N[C@@H](Cc1c[nH]cn1)C(=O)O.[Na].[Zn]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.45
CYP3A4 P08684 2/20 0.45
CYP1A2 P05177 1/20 0.44
PKM P14618 2/20 0.41
ALPI P09923 1/20 0.41
PTGS1 P23219 1/20 0.41
XIAP P98170 1/20 0.41
GRIA2 P42262 4/20 0.39
GRIA1 P42261 3/20 0.39
GRIA3 P42263 3/20 0.39
GRIA4 P48058 3/20 0.39
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
BLM P54132 2/20 0.38
PMP22 Q01453 2/20 0.38
KMT2A Q03164 2/20 0.38
HIF1A Q16665 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL30038780 0.98 SLC7A5 (0.46) SLC7A5CYP3A4CYP1A2PKMALPI
D-Histidine SCHEMBL28977992 0.98 SLC7A5 (0.46) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL123617 0.98 SLC7A5 (0.46) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL6005504 0.98 SLC7A5 (0.46) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL1032558 0.98 SLC7A5 (0.46) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL32678352 0.97 SLC7A5 (0.45) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL31754612 0.97 SLC7A5 (0.45) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL2782310 0.97 SLC7A5 (0.45) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL2782319 0.97 SLC7A5 (0.45) SLC7A5CYP3A4CYP1A2PKMALPI
Histidine SCHEMBL32678354 0.97 SLC7A5 (0.45) SLC7A5CYP3A4CYP1A2PKMALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104886-A1 METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY 유엔케이코리아 주식회사 2026-05-21 WO disclosed
US-12350352-B2 Composition for surface modification LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2025-07-08 US disclosed
EP-4464307-A1 COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME MPLUS COSMETICS S.R.L. (IT) 2024-11-20 EP disclosed
US-20240374498-A1 COSMETIC COMPOSITION AND METHODS OF MAKING THE SAME MPLUS COSMETICS S.R.L. (IT) 2024-11-14 US disclosed
EP-3342395-B1 COMPOSITION FOR HAIR SURFACE MODIFICATION LG HOUSEHOLD & HEALTH CARE LTD (KR) 2024-08-07 EP disclosed
EP-4406617-A2 COMPOSITION FOR SURFACE MODIFICATION LG Household & Health Care Ltd. (KR) 2024-07-31 EP disclosed
CN-116490598-A Detergent compositions with enhanced efficacy delivery of substances 株式会社LG生活健康 2023-07-25 CN disclosed
US-11612552-B2 Composition for surface modification LG HOUSEHOLD & HEALTH CARE LTD. 2023-03-28 US disclosed
US-20230088314-A1 Composition For Surface Modification LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2023-03-23 US disclosed
WO-2022114681-A1 CLEANSER COMPOSITION WITH ENHANCED ACTIVE SUBSTANCE DELIVERY 주식회사 엘지생활건강 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12350352-B2 Composition for surface modification CUTA, PTMS, DNMT1 SLC7A5 4300/4885CYP3A4 597/4885CYP1A2 676/4885
US-20230088314-A1 Composition For Surface Modification CUTA, PTMS, DNMT1 SLC7A5 4300/4885CYP3A4 597/4885CYP1A2 676/4885
US-11612552-B2 Composition for surface modification CUTA, PTMS, DNMT1 SLC7A5 4300/4885CYP3A4 597/4885CYP1A2 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.